Count on us for updates on the coronavirus and guidance for cancer patients and family members.Read the latest articles
Sara Tolaney, MD, MPH, is the Associate Director for the Susan F. Smith Center for Women’s Cancers, the Director of Clinical Trials in the Breast Oncology Center, Director of Breast Immunotherapy Clinical Research, Senior Physician at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School. Her research focuses on the development of novel therapies in the treatment of breast cancer.
Dr. Tolaney is Principal Investigator (PI) of many therapeutic clinical trials and translational studies for breast cancer. Dr. Tolaney serves as the Breast Cancer Leader for the Early Drug Development Center (EDDC) and the for Center for Immuno-Oncology (CIO) at Dana-Farber Cancer Institute. She has developed many novel immunotherapy combination trials, many of which are currently ongoing. She is the recipient of the Lee M. Nadler “Extra Mile” Award, and the Innovation Award for Clinical Faculty at Dana-Farber Cancer Institute.
Dr. Tolaney received her undergraduate degree from Princeton University and her medical degree from UC San Francisco. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained her Masters in Public Health from Harvard School of Public Health.